The Relative Strength (RS) Rating for McKesson jumped into a new percentile Wednesday, as it got a lift from 66 to 79.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research shows that the market's biggest winners often have an RS Rating of over 80 as they begin their largest climbs. See if McKesson can continue to rebound and clear that threshold.
McKesson is now considered extended and out of buy range after clearing a 709.50 buy point in a first-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
EPS growth dropped last quarter from 64% to 5%, but the top line rose from 19% to 23%.
The company earns the No. 2 rank among its peers in the Medical-Wholesale Drugs industry group. is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
